None
Quote | Mateon Therapeutics Inc. (OTCMKTS:MATN)
Last: | $0.26 |
---|---|
Change Percent: | 8.33% |
Open: | $0.235 |
Close: | $0.26 |
High: | $0.27 |
Low: | $0.221 |
Volume: | 108,017 |
Last Trade Date Time: | 03/29/2021 04:55:56 pm |
News | Mateon Therapeutics Inc. (OTCMKTS:MATN)
AGOURA HILLS, California, March 15, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) today announced the regulatory approval from the Ministry of Food and Drug Safety of Korea for the phase 1b clinical trial of a patented OT-101/IL-2 combination. This phase 1b clinical trial w...
PART 1 AND 2 SENTINEL PATIENTS COMPLETED TREATMENT THE FIRST COHORT OF 18 PART 1 PATIENTS COMPLETED TREATMENT. AGOURA HILLS, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (“Mateon”) (OTCQB:MATN) announced today that it has completed t...
Message Board Posts | Mateon Therapeutics Inc. (OTCMKTS:MATN)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Mateon Therapeutics Inc. Company Name:
MATN Stock Symbol:
OTCMKTS Market:
Mateon Therapeutics Inc. Website:
AGOURA HILLS, California, March 15, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) today announced the regulatory approval from the Ministry of Food and Drug Safety of Korea for the phase 1b clinical trial of a patented OT-101/IL-2 combination. This phase 1b clinical trial w...
PART 1 AND 2 SENTINEL PATIENTS COMPLETED TREATMENT THE FIRST COHORT OF 18 PART 1 PATIENTS COMPLETED TREATMENT. AGOURA HILLS, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (“Mateon”) (OTCQB:MATN) announced today that it has completed t...
AGOURA HILLS, California, March 01, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious disease and respiratory health, and Windlas Biotech Pvt. Ltd. (Windlas), a leading I...